Activity-Regulated Cytoskeleton-Associated Protein and Response to Cognitive Behavioral Therapy in First-Episode Psychosis
Poster C39, Wednesday, October 10, 11:30 am - 1:00 pm, Essex Ballroom
Jacob G. Pine1, Aubrey M. Moe1, Amelia L. Gallitano2, Nicholas J.K. Breitborde1; 1Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, 2Department of Basic Medical Sciences, University of Arizona
Research suggests that early treatment for psychotic disorders is instrumental to improving long-term illness outcomes. Yet, outcomes to early intervention for psychosis are heterogeneous, which suggests a need for further research to identify predictors of who will be most responsive to treatment. One promising predictor variable is the gene activity-regulated cytoskeleton-associated protein (ARC). ARC has been previously related to risk for schizophrenia, as well as other domains of functioning in human and nonhuman samples. More recently, ARC has been shown to predict the magnitude of response to metacognitive remediation therapy among individuals with first-episode psychosis; possibly due to its role in mediating neurobiological processes underlying learning and memory. The current study seeks to expound upon the results of this previous study and investigate the relationship between ARC gene expression and cognitive behavioral therapy symptom response in a sample with first-episode psychosis.
Topic Area: Psychosocial Interventions